Nucleus, CAR T

CAR T Cell-induced Interferon Gamma Enhances MHC Class I Expression and Sensitizes Neuroblastoma to TCR-engineered T Cell Therapy

Authors from Charité University Medical Center Berlin, German Cancer Consortium, the Princess Máxima Center for Pediatric Oncology in Utrecht, and University Hospital Essen have demonstrated that neuroblastoma evades T cell receptor (TCR) recognition by keeping major histocompatibility complex (MHC) class I low. However, chimeric antigen receptor (CAR) T cells attacking the same tumor release enough interferon gamma (IFNγ) to force that expression back up. Published in Frontiers in Immunology, the study supports giving CAR and TCR T cell products in sequence.

Neuroblastoma is the most common extracranial solid tumor of childhood and arises from neural crest precursors with intrinsically reduced MHC class I, which limits TCR-engineered therapy against antigens such as NY-ESO-1. Antigen expression is also heterogeneous, so CAR T cells leave antigen-negative subpopulations behind. The authors screened 27 neuroblastoma cell lines for surface HLA-A,B,C before and after IFNγ exposure, then used LAN-1 cells as the model. Primary human T cells were engineered either with an L1CAM-targeted CAR, knocked into the TRAC locus by non-viral CRISPR/Cas9, or with an HLA-A*02:01-restricted NY-ESO-1 TCR. Killing was quantified by IncuCyte real-time assays, alone or sequentially, including against 1:1 mixtures of parental and CRISPR-generated L1CAM-knockout cells, with confirmation in NSG xenografts and a syngeneic GD2-CAR model.

IFNγ raised HLA-A,B,C in most lines, with NB69 and SK-N-SH resistant. NY-ESO-1 TCR T cells, enriched from 22.4% ± 13.04% to 74.7% ± 16.9% (n = 5), killed poorly alone but produced a 92.8% ± 0.34% reduction in tumor expansion after IFNγ pretreatment (p = 0.0597, n = 3). CAR T cell pretreatment gave a 76.5% ± 14.7% reduction (n = 3), with higher CD25 and CD137 expression (p = 0.0204 and p = 0.0112) and HLA-A02 upregulation (p = 0.0003). In mixed cultures, sequential treatment cut expansion by 59.8% ± 10.6% in parental and 87.4% ± 9.8% in L1CAM-knockout cells, converting antigen-negative cells into TCR targets. In vivo HLA-A*02 induction peaked by day 7 without reaching significance. Thus, sequential CAR and TCR T cell therapy addresses two barriers at once in preclinical neuroblastoma models, using CAR-derived IFNγ to restore MHC class I and to bring antigen-negative tumor cells within reach of TCR-mediated killing.

Reference

Vitali A, Padlo J, Caramel C, et al. CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. Front Immunol. 2026;17:1901504. https:doi.org/10.3389/fimmu.2026.1901504